The Agency for Toxic Substances and Disease Registry (ATSDR) has published results of the community wide JAK2 screening conducted in Schuylkill, Carbon and Luzerne counties in PA. In 2008 this tri-county area was found to have a higher than average prevalence of Polycythemia Vera. The response has been a multi-disciplinary effort to examine the situation.… Read More »REPORT ON JAK2 COMMUNITY SCREENING IN PENNSYLVANIA
The International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory scientists. Its main goal is to provide a forum for scientific exchange and collaboration on topics related to MPN/MPD. A recent study carried out on behalf of the IWG-MRT documents a new model for predicting survival for… Read More »STUDY PUBLISHED ON NEW PROGNOSTIC TOOL
By Lindsay Braun, Ivanhoe Health Correspondent ORLANDO, Fla. (Ivanhoe Newswire) — A breakthrough discovery reveals one particular hormone is responsible for helping a cancer enzyme cause a type of deadly red blood cell cancer. Thomas Bumm, M.D., lead researcher and member of the Oregon Health & Science University Cancer Institute was working with the JAK2… Read More »NEW CANCER DISCOVERY, HORMONE TO BLAME
July 22, 2009 The COMFORT-1 (COntrolled MyeloFibrosis Study with ORal Jak Treatment) trial will test the drug INCB18424 in patients with Primary Myelofibrosis, post-Polycythemia Vera Myelofibrosis or post-Essential Thrombocythemia Myelofibrosis. The Special Protocol Assessment (SPA) for the design of the trial is related to reduction in spleen size, a goal Incyte is confident they will… Read More »INCYTE REACHES AGREEMENT WITH FDA ON MF DRUG
Results Presented June 2, 2008 at the 2008 American Society of Clinical Oncology Annual Meeting WILMINGTON, Del.–(BUSINESS WIRE)–June 2, 2008–Incyte Corporation (Nasdaq: INCY) announced today the presentation of clinical results from a Phase I/II study of INCB18424, its orally available janus-associated kinase (JAK) inhibitor, in patients with myelofibrosis. Myelofibrosis (MF) is a serious neoplastic condition… Read More »INCYTE’S NOVEL JAK INHIBITOR DEMONSTRATES RAPID CLINICAL BENEFITS IN ONGOING PHASE I/II MYELOFIBROSIS STUDY
Thank you for joining us on our new website, or what we did this summer. Please take a look around, try out some of the new features and let us know what you think. Our goals during development were to offer more and better information and access for MPN patients, their families, friends, and doctors. Our site is… Read More »MPN RESEARCH FOUNDATION LAUNCHES NEW WEBSITE
With this survey, the MPN Research Foundation wants to learn more about what kind of information you want to see from us and how you want to receive it. Thank you in advance for your help! https://www.surveymonkey.com/r/HSJKY3Q?embedded=1
Dr. Ruben Mesa and Dr. Robyn Scherber hematologists from the Mays Cancer Center, home to UT Health San Antonio MD Anderson discuss the latest updates regarding new treatments for myeloproliferative neoplasms (MPNS) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). They also discuss the latest updates from the 2019 American Society of Hematology… Read More »MPNS UPDATE – SPRING 2020
Good news in upcoming therapies for myeloproliferative neoplasms. CTI Biopharma has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the development of Pacritinib in the treatment of Myelofibrosis. “Since the initiation of the PACIFICA trial in September 2019, we have been working diligently with the FDA to identify an expedited… Read More »CTI BIOPHARMA GRANTED FAST TRACK DESIGNATION FOR MYELOFIBROSIS TREATMENT
